Novo Nordisk A/S – Share repurchase programme
November 03 2020 - 2:54PM
Novo Nordisk A/S – Share repurchase programme
Novo Nordisk A/S – Share repurchase
programme
Bagsværd, Denmark, 3 November 2020 — As part of
the up to DKK 17 billion 2020 share repurchase programme, Novo
Nordisk A/S has now initiated a new share repurchase programme for
an amount of up to DKK 2.7 billion in accordance with Article 5 of
Regulation No 596/2014 of the European Parliament and Council of 16
April 2014 (MAR) and the Commission Delegated Regulation (EU)
2016/1052 of 8 March 2016 (the "Safe Harbour Rules”).
For that purpose, Novo Nordisk A/S has appointed Nordea Danmark,
Filial af Nordea Bank Abp, as lead manager to execute the programme
independently and without influence from Novo Nordisk A/S. The
purpose of the programme is to reduce the company’s share capital
and to meet obligations arising from share-based incentive
programmes. Under the agreement, Nordea Danmark, Filial af Nordea
Bank Abp, will repurchase B shares on behalf of Novo Nordisk A/S
during the trading period starting 4 November 2020 and ending on 1
February 2021.
A maximum of 201,463,131 B shares in total can be bought during
the trading period. The maximum number of B shares that can be
repurchased on a single trading day may not exceed 20% of the
average daily trading volume of Novo Nordisk B shares on the
trading venue, on which the purchase takes place, in the preceding
20 trading days of the purchase (excluding the day of the
purchase). At least once every seven trading days, Novo Nordisk A/S
will issue an announcement in respect of the transactions made
under the repurchase programme.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat diabetes and other serious chronic diseases such as
obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines and working to prevent and ultimately cure disease. Novo
Nordisk employs about 44,000 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media: |
|
|
Mette Kruse
Danielsen |
+45 4442
3883 |
mkd@novonordisk.com |
Ken Inchausti
(US) |
+1 609 240
9429 |
kiau@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075
2175 |
dabo@novonordisk.com |
Valdemar Borum
Svarrer |
+45 3079
0301 |
jvls@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075
2253 |
arnd@novonordisk.com |
Mark Joseph
Root |
+45 3079
4211 |
mjhr@novonordisk.com |
Kristoffer Due
Berg US) |
+1 609 235
2989 |
krdb@novonordisk.com |
Company announcement No 65 / 2020
- PR20201103 - SH initiation
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jul 2023 to Jul 2024